维奈克拉联合低强度化疗治疗成人急性淋巴细胞白血病
这项1b期研究纳入19例急性淋巴细胞白血病患者,其中新诊断(≥60岁)11例、复发/难治(≥18岁)8例,接受维奈克拉联合减量mini-HCVD方案。新诊断组10/11例(90.9%)达到可测量残留病阴性完全缓解,中位无病生存期54.6个月;复发/难治组3/8例(37.5%)达到完全缓解。
要点
- 维奈克拉联合mini-HCVD在新诊断急性淋巴细胞白血病中耐受良好且疗效可观。
- 新诊断组10/11例(90.9%)达到可测量残留病阴性完全缓解,含6例低二倍体TP53突变患者。
- 中位随访60个月,新诊断组中位无病生存期54.6个月,2年无病生存率90%(95%CI 71-100)。
核心结论
- 对于新诊断的急性淋巴细胞白血病患者,维奈克拉联合mini-HCVD耐受良好且疗效可观。
研究设计与样本
- 1b期研究,纳入19例急性淋巴细胞白血病患者,新诊断组11例(年龄≥60岁,B细胞8例、T细胞3例),复发/难治组8例(年龄≥18岁,B细胞3例、T细胞5例)。
- 维奈克拉每周期给药21天,联合mini-HCVD方案(环磷酰胺、长春新碱、地塞米松与甲氨蝶呤和阿糖胞苷交替)。
- 剂量水平1(DL1,n=3,400 mg/d)和剂量水平2(DL2,n=6,600 mg/d)均未出现剂量限制性毒性,DL2为推荐2期剂量并进一步探索(n=10)。
主要发现
- 最常见非血液学不良事件为≥3级感染。
- 60天内无死亡,未发生肿瘤溶解综合征、肝毒性、持续性血细胞减少或因毒性提前停药。
- 新诊断组10/11例(90.9%)达到可测量残留病阴性(灵敏度<0.01%)的完全缓解,包括6例低二倍体TP53突变患者。
- 新诊断组所有完全缓解患者均桥接至造血干细胞移植(n=9)或完成方案(n=1)。
- 中位随访60个月,新诊断组中位无病生存期54.6个月(95%CI 35.5至不可评估),2年无病生存率90%(95%CI 71-100);复发/难治组3/8例(37.5%)达到完全缓解。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In acute lymphoblastic leukemia (ALL), the B-cell lymphoma 2 inhibitor venetoclax may enhance the efficacy of chemotherapy, allowing dose reductions. This phase 1b study of venetoclax plus attenuated chemotherapy enrolled 19 patients with ALL either newly diagnosed (aged ≥60 years, n = 11 [B-cell, n = 8; T-cell, n = 3]) or relapsed/refractory (R/R; aged ≥18 years, n = 8 [B-cell, n = 3; T-cell, n = 5]). Venetoclax was given for 21 days with each cycle of mini-hyper-CVD (mini-HCVD; cyclophosphamide, vincristine, dexamethasone alternating with methotrexate and cytarabine). There were no dose-limiting toxicities at dose level 1 (DL1; n = 3, 400 mg/d) or DL2 (n = 6, 600 mg/d); DL2 was the recommended phase 2 dose and explored further (n = 10). The most common nonhematologic adverse events were grade ≥3 infections. There were no deaths within 60 days. There was no tumor lysis syndrome, hepatotoxicity, prolonged cytopenias, or early discontinuation for toxicity. Among patients with newly diagnosed ALL, 10 of 11 (90.9%) achieved a measurable residual disease-negative (<0.01% sensitivity) complete remission (CR) including 6 patients with hypodiploid TP53-mutated ALL. All patients in CR bridged to hematopoietic stem cell transplant (n = 9) or completed protocol (n = 1). With a median follow-up of 60 months, median disease-free survival (DFS) for patients with newly diagnosed ALL was 54.6 months (95% confidence interval [CI], 35.5 to not available), with a 2-year DFS rate of 90% (95% CI, 71-100). Among patients with R/R ALL, 3 of 8 (37.5%) achieved CR. In summary, for patients with newly diagnosed ALL, venetoclax plus mini-HCVD is well tolerated with promising efficacy. This trial was registered at www.clinicaltrials.gov as #NCT03319901.
引用
- Luskin MR, Shimony S, Keating J, et al. Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia. Blood Adv. 2025. PMID: 39546748. doi:10.1182/bloodadvances.2024014405
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。